Skip to main content

LIVE

ESLA

Estrella Immunopharma, Inc.

ESLA

NASDAQ·Healthcare·Biotechnology·Mkt cap $27.6M

$0.65

+0.83%

P/E

-2.63

Mkt Cap

$27.6M

52-Wk Range

$0.59–$3.15

52-Week Range

$0.59 - $3.15

P/E

-2.63

Fwd P/E

-2.59

Beta

0.89

Div Yield

0.00%

Avg Vol

37.4K

Shares Out

42.7M

Mkt Cap

$27.6M

Price action

Price chart

Down 35.4% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary T-cell engineering technology platform
  • Strategic partnership with Imugene Limited for solid tumor expansion
  • Focused pipeline targeting high-incidence cancers with significant market opportunity
  • Early-stage positioning allowing for rapid advancement and potential breakthrough designations

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Clinical trial initiation and advancement of EB103 and EB104 candidates

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Falling

-42.8% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Sep 2, 2026

Q3 26 RECAP

AUG 13, 2026

Reported EPS of -$0.05 vs -$0.09 consensus (+44.4% surprise).

EPS beat +44.4%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+44.4%

Revenue trend · last 8Q

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

vs Industry

How ESLA stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.